Asthma- Pipeline Insight, 2023

Asthma- Pipeline Insight, 2023

DelveInsight’s, “Asthma- Pipeline Insight, 2023,” report provides comprehensive insights about 90+ companies and 100+ pipeline drugs in Asthma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Asthma Understanding

Asthma: Overview

Asthma is a chronic disease that affects the airways. Asthma is characterized by inflammation and spasm of the airways. The airways are tubes that carry air in and out of the lungs. If a person has asthma, the inside walls of the airways become sore and swollen. The air passages in the lungs become narrow due to inflammation and tightening of the muscles around the small airways. This causes asthma symptoms: cough, wheeze, shortness of breath, and chest tightness. Asthma is a chronic disease that affects the airways. Asthma is characterized by inflammation and spasm of the airways. The airways are tubes that carry air in and out of the lungs. If a person has asthma, the inside walls of the airways become sore and swollen. The air passages in the lungs become narrow due to inflammation and tightening of the muscles around the small airways. This causes asthma symptoms: cough, wheeze, shortness of breath, and chest tightness. Symptoms of asthma vary from person to person. A person may have infrequent asthma attacks or have symptoms only at a certain time such as when exercising or may have symptoms all the time. Symptoms of asthma resemble many respiratory infections. Common symptoms: Shortness of breath, Chest tightness, pain or pressure, Coughing (especially at night), Wheezing, Trouble sleeping caused by shortness of breath, coughing or wheezing. The first step in asthma diagnosis is a careful clinical history; identifying the characteristic symptoms and their duration, intensity, and relationship of symptoms with allergen and triggering agent; and the impact of these symptoms on the quality of life. If symptoms are present, a physician will perform a physical examination to rule out other possible conditions, such as a respiratory infection or chronic obstructive pulmonary disease (COPD). If the physician concludes that there is no evidence of a respiratory infection or COPD, then tests are performed to check lung function. There is no cure for asthma. However, it can be controlled with medication which may help to prevent or relieve the symptoms of asthma. Asthma is a chronic disease. It has to care for all the time not just when the symptoms are present. Asthma can be managed if a patient can identify and minimize contact with triggers; understand and take medications; recognize signs when they get worse and manage them and know what to do when asthma gets worse. Preventive measures play a vital role in managing and treating asthma. A patient may avoid all the allergen or triggering agents like dust, cold air, pollen, pet dander, smoke, perfumes, or allergy of any other kind. If a patient has aspirin-induced asthma, then they should avoid taking aspirin or any other NSAIDs. Food containing sulfites must be avoided by an asthmatic patient. The right medication depends on a number of things- age, symptoms, asthma trigger and what works best for a patient to control symptoms.

""Asthma- Pipeline Insight, 2023"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Asthma pipeline landscape is provided which includes the disease overview and Asthma treatment guidelines. The assessment part of the report embraces, in depth Asthma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Asthma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Asthma R&D. The therapies under development are focused on novel approaches to treat/improve Asthma.

Asthma Emerging Drugs Chapters

This segment of the Asthma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Asthma Emerging Drugs

Dexpramipexole: Areteia Therapeutics

Dexpramipexole inhibits the maturation and release of eosinophils in bone marrow, based on evidence from cell cultures and human biopsies, thereby lowering peripheral blood eosinophil levels. Most recently in a Phase II study (EXHALE-1) in patients with moderate-to-severe eosinophilic asthma, treatment with dexpramipexole resulted in a significant, dose-dependent reduction in blood absolute eosinophil count at all doses tested (dexpramipexole doses of 37.5 mg, 75 mg, or 150 mg twice daily) compared to placebo. Dexpramipexole was well tolerated in the trial, with adverse events balanced across treatment and placebo groups, no serious adverse events, and no adverse events leading to discontinuation. Currently the drug is in Phase III stage of clinical trial evaluation for the treatment of Eosinophilic Asthma.

TQC2731: Chia Tai Tianqing Pharmaceutical Group

TQC2731, belongs to the class of Antiasthmatic. These anti-inflammatory drugs are the most effective and commonly used long-term control medications for asthma. They reduce swelling and tightening in the airways. An Antiasthmatic and antiallergic agent also prevents mast cell release of histamine and formation of other mediators (leukotrienes) of anaphylaxis by inhibiting degranulation after contact with antigens. These helps prevent symptoms of asthma, allergic rhinitis, mastocytosis, and exercise-induced bronchospasm.TQC2731 is currently being investigated in Phase II stage of Clinical trial evaluation for the treatment of Asthma.

SHR-1703: Jiangsu HengRui Medicine

SHR-1703 injection is a humanized anti- IL-5 monoclonal antibody ( IgG1 subtype) that can bind to IL-5 , inhibit the IL-5/IL-5R signaling pathway, and thereby inhibit the proliferation and activation of eosinophils And migration. Reduce the number of asthma attacks in patients with eosinophilic asthma, improve the lung function of patients, and improve the quality of life of patients. The drug is currently in Phase II stage of clinical trial evaluation to treat Asthma.

Further product details are provided in the report……..

Asthma: Therapeutic Assessment

This segment of the report provides insights about the different Asthma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Asthma

There are approx. 100+ key companies which are developing the therapies for Asthma. The companies which have their Asthma drug candidates in the most advanced stage, i.e. phase III include, Areteia Therapeutics.

Phases

DelveInsight’s report covers around 100+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Asthma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Asthma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Asthma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Asthma drugs.

Asthma Report Insights

Asthma Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Asthma Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Asthma drugs?

How many Asthma drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Asthma?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Asthma therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Asthma and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Jiangsu Hengrui Medicine

GlaxoSmithKline

Immunotek SL

AB Science

EMS

Avalo Therapeutics

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

ARS Pharmaceuticals

Sanofi

Zura Bio Ltd.

AstraZeneca

EURRUS Biotech GmbH

T-Balance Therapeutics GmbH

Gossamer Bio

Aldeyra Therapeutics, Inc.

Trio Medicines

Janssen Research & Development

Arrowhead Pharmaceuticals

Hoffman-La-Roche

GlaxoSmithKline

Biohaven Pharmaceutical

TAK-Circulator Co.

Shanghai Hengrui Pharmaceutical

Key Products

GSK3511294

MM09-MG01

Masitinib

Budesonide / Formoterol

AVTX-002

610

Neffy

Amlitelimab

Torudokimab

AZD1402

XC8

Tregalizumab

GB001

ADX-629

TR4

MEDI 3506

Lumicitabine

ARO-MUC5AC

RG6341

GSK3923868

Zavegepant

TAKC-02

SHR-1819